<Disease><Name>G(M2)-GANGLIOSIDOSIS: VARIANT B, TAY-SACHS DISEASE</Name><Synonym>G(M2)-GANGLIOSIDOSIS WITH HEXOSAMINIDASE A DEFICIENCY</Synonym><OMIM><Number>272800</Number><URL>http://omim.org/entry/272800</URL></OMIM><Orphanet><Number>845</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=845</URL></Orphanet><Protein><Number>Beta-hexosaminidase subunit alpha</Number><URL>http://www.uniprot.org/uniprot/P06865</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>15q23</Gene><ICD>E75.0</ICD><Summary>rare (1:320000 );autosomal recessive ;mutation in the alpha subunit of the hexosaminidase A gene;3 types: ;- infantile, acute form (classical Tay-Sachs disease) ;- subacute form ;- chronic form</Summary><Symptoms><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2211</id><symptom>blindness, visual loss, visual impairment</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1733</id><symptom>cherry-red spot on retinal macula</symptom><category>EYES</category></symtomp><symtomp><id>2117</id><symptom>CT, brain, abnormalities [-] / CT, kraniell, abnormal </symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2302</id><symptom>dysostosis multiplex</symptom><category>SKELATAL DEFECT</category></symtomp><symtomp><id>2105</id><symptom>encephalopathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1715</id><symptom>infections (severe or recurrent)</symptom><category>GENERAL TOPICS | IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>1887</id><symptom>macrocephaly (large calvaria, &gt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1900</id><symptom>myoclonus</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1958</id><symptom>psychosis</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1974</id><symptom>spastic diplegia/quadriplegia/tetraplegia</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>918</id><name>Hexosaminidase A</name><specimen>serum</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>919</id><name>Hexosaminidase A</name><specimen>fibroblasts</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>920</id><name>Hexosaminidase B</name><specimen>fibroblasts</specimen><value>normal/inc</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>965</id><name>Oligosaccharides</name><specimen>urine</specimen><value>abnormal</value><min>    </min><max>    </max><unit>not detectable</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7955</id><title>Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases</title><author>Lyn N,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>92</pages><co_aut>et al.</co_aut></literature><literature><id>4503</id><title>The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy</title><author>Regier DS,</author><journal>Pediatr Endocrinol Rev Suppl</journal><year>2016</year><book /><volume>13</volume><number>1</number><pages>663-673</pages><co_aut>et al.</co_aut></literature><literature><id>1799</id><title>Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy</title><author>Meikle PJ</author><journal>Pediatrics</journal><year>2004</year><book /><volume>114</volume><number>4</number><pages>909-916</pages><co_aut>et al.</co_aut></literature><literature><id>156</id><title>The GM2 gangliosidoses</title><author>Gravel RA</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>92</number><pages>2839-2879</pages><co_aut>Clarke JTR, Kaback MM, Mahuran D, Sandhoff K, Suzuki K</co_aut></literature><literature><id>248</id><title>Collaborative study of the molecular epidemiology of Tay-Sachs disease in Europe</title><author>Akli S</author><journal>Eur J Hum Genet</journal><year>1993</year><book /><volume>1</volume><number>3</number><pages>229-238</pages><co_aut>et al.</co_aut></literature><literature><id>249</id><title>Tay-Sachs disease: progression of changes on neuroimaging in four cases</title><author>Fukumizu M</author><journal>Neuroradiology</journal><year>1992</year><book /><volume>34</volume><number>6</number><pages>483-486</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>